{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:12:33Z","timestamp":1780441953412,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01876-9","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T21:20:20Z","timestamp":1668028820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The clinical significance of HER2 expression in DCIS"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5939-5041","authenticated-orcid":false,"given":"Ioanna","family":"Akrida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesk","family":"Mulita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"6","key":"1876_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351. https:\/\/doi.org\/10.3322\/caac.21583.","journal-title":"CA Cancer J Clin"},{"key":"1876_CR2","unstructured":"American Cancer Society. How Common Is Breast Cancer? Available at: https:\/\/www.cancer.org\/cancer\/breast-cancer\/about\/how-common-is-breast-cancer.html (Accessed on June 27, 2022)"},{"issue":"6","key":"1876_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/tbj.13860","volume":"26","author":"MD Lagios","year":"2020","unstructured":"Lagios MD. Duct carcinoma in situ: a personal perspective. Breast J. 2020;26(6):1132\u20137. https:\/\/doi.org\/10.1111\/tbj.13860.","journal-title":"Breast J"},{"issue":"4","key":"1876_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J. PRECISION team. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285\u201392. https:\/\/doi.org\/10.1038\/s41416-019-0478-6.","journal-title":"Br J Cancer"},{"issue":"4","key":"1876_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","volume":"21","author":"LJ Solin","year":"2019","unstructured":"Solin LJ. Management of ductal carcinoma in situ (DCIS) of the breast: present approaches and future directions. Curr Oncol Rep. 2019;21(4):33. https:\/\/doi.org\/10.1007\/s11912-019-0777-3.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1876_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","volume":"105","author":"LJ Solin","year":"2013","unstructured":"Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701\u201310. https:\/\/doi.org\/10.1093\/jnci\/djt067.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"1876_CR7","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirstr\u00f6m K, Zhou W, Amini RM, W\u00e4rnberg F. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895\u2013901. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0842.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1876_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, StringerReasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Breast cancer version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"1876_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/biomedicines10051061","volume":"10","author":"J Solek","year":"2022","unstructured":"Solek J, Chrzanowski J, Cieslak A, Zielinska A, Piasecka D, Braun M, Sadej R, Romanska HM. Subtype-specific tumour immune microenvironment in risk of recurrence of ductal carcinoma in situ: prognostic value of HER2. Biomedicines. 2022;10(5):1061. https:\/\/doi.org\/10.3390\/biomedicines10051061.","journal-title":"Biomedicines"},{"issue":"2","key":"1876_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28(2):321\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw623.","journal-title":"Ann Oncol"},{"issue":"2","key":"1876_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, Rakha EA. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71(2):258\u201368. https:\/\/doi.org\/10.1111\/his.13217.","journal-title":"Histopathology"},{"issue":"41","key":"1876_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jncimonographs\/lgq040","volume":"2010","author":"MJ Silverstein","year":"2010","unstructured":"Silverstein MJ, Lagios MD. Choosing treatment for patients with ductal Carcinoma in situ: fine tuning the University of Southern California\/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr. 2010;2010(41):193\u20136. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq040.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"23","key":"1876_CR13","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","volume":"28","author":"U Rudloff","year":"2010","unstructured":"Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.26.8847.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1876_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10549-017-4553-5","volume":"167","author":"RS Punglia","year":"2018","unstructured":"Punglia RS, Jiang W, Lipsitz SR, Hughes ME, Schnitt SJ, Hassett MJ, Nekhlyudov L, Achacoso N, Edge S, Javid SH, Niland JC, Theriault RL, Wong YN, Habel LA. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018;167(3):751\u20139. https:\/\/doi.org\/10.1007\/s10549-017-4553-5.","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"1876_CR15","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-21-1239","volume":"27","author":"MA Thorat","year":"2021","unstructured":"Thorat MA, Levey PM, Jones JL, Pinder SE, Bundred NJ, Fentiman IS, Cuzick J. Prognostic and predictive value of her2 expression in ductal carcinoma in situ: results from the UK\/ANZ DCIS Randomized trial. Clin Cancer Res. 2021;27(19):5317\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1239.","journal-title":"Clin Cancer Res"},{"key":"1876_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-015-1479-3","volume":"15","author":"S Borgquist","year":"2015","unstructured":"Borgquist S, Zhou W, Jirstr\u00f6m K, Amini RM, Sollie T, S\u00f8rlie T, Blomqvist C, Butt S, W\u00e4rnberg F. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. 2015;15:468. https:\/\/doi.org\/10.1186\/s12885-015-1479-3.","journal-title":"BMC Cancer"},{"issue":"9","key":"1876_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/1940-6207.CAPR-20-0024","volume":"13","author":"TJ O'Keefe","year":"2020","unstructured":"O\u2019Keefe TJ, Blair SL, Hosseini A, Harismendy O, Wallace AM. HER2-overexpressing ductal carcinoma in situ associated with increased risk of ipsilateral invasive recurrence, receptor discordance with recurrence. Cancer Prev Res (Phila). 2020;13(9):761\u201372. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0024.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"1876_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.breast.2013.04.001","volume":"22","author":"JM Noh","year":"2013","unstructured":"Noh JM, Lee J, Choi DH, Cho EY, Huh SJ, Park W, Nam SJ, Lee JE, Kil WH. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast. 2013;22(5):894\u20137. https:\/\/doi.org\/10.1016\/j.breast.2013.04.001.","journal-title":"Breast"},{"issue":"11","key":"1876_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-019-0436-3","volume":"120","author":"IM Miligy","year":"2019","unstructured":"Miligy IM, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer. 2019;120(11):1075\u201382. https:\/\/doi.org\/10.1038\/s41416-019-0436-3.","journal-title":"Br J Cancer"},{"issue":"4","key":"1876_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/annonc\/mdv013","volume":"26","author":"G Curigliano","year":"2015","unstructured":"Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol. 2015;26(4):682\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv013.","journal-title":"Ann Oncol"},{"issue":"3","key":"1876_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/tbj.12735","volume":"23","author":"P Di Cesare","year":"2017","unstructured":"Di Cesare P, Pavesi L, Villani L, Battaglia A, Da Prada GA, Riccardi A, Frascaroli M. The relationships between HER2 overexpression and DCIS characteristics. Breast J. 2017;23(3):307\u201314. https:\/\/doi.org\/10.1111\/tbj.12735.","journal-title":"Breast J"},{"issue":"5","key":"1876_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/annonc\/mdv062","volume":"26","author":"KE Williams","year":"2015","unstructured":"Williams KE, Barnes NLP, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol. 2015;26(5):1019\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv062.","journal-title":"Ann Oncol"},{"issue":"15","key":"1876_CR23","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-18-0201","volume":"24","author":"LL Visser","year":"2018","unstructured":"Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ-a nested case-control study. Clin Cancer Res. 2018;24(15):3593\u2013601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0201.","journal-title":"Clin Cancer Res"},{"key":"1876_CR24","first-page":"7","volume":"2","author":"S Nofech-Mozes","year":"2008","unstructured":"Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W. Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol. 2008;2:7\u201318.","journal-title":"Clin Med Oncol"},{"issue":"1","key":"1876_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/PAI.0000000000000223","volume":"24","author":"JE Davis","year":"2016","unstructured":"Davis JE, Nemesure B, Mehmood S, Nayi V, Burke S, Brzostek SR, Singh M. Her2 and Ki67 biomarkers predict recurrence of ductal carcinoma in situ. Appl Immunohistochem Mol Morphol. 2016;24(1):20\u20135. https:\/\/doi.org\/10.1097\/PAI.0000000000000223.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1876_CR26","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.21037\/tcr-20-1481","volume":"9","author":"DH Gong","year":"2020","unstructured":"Gong DH, Ge JY, Chen YY, Ding KF, Yu KD. HER2 overexpression in ductal carcinoma in situ is associated with ipsilateral breast cancer recurrence after conservative surgery. Transl Cancer Res. 2020;9(6):3787\u201393. https:\/\/doi.org\/10.21037\/tcr-20-1481.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"1876_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4048\/jbc.2017.20.4.327","volume":"20","author":"K Kim","year":"2017","unstructured":"Kim K, Kim JH, Kim YB, Suh CO, Shin KH, Kim JH, Kim TH, Jung SY, Choi DH, Park W, Ahn SD, Kim SS, Yea JW, Kang MK, Kim DW, Kim YJ. Selective radiation therapy for ductal carcinoma in situ following breast-conserving surgery according to age and margin width: Korean Radiation Oncology Group 11\u201304 and 16\u201302 Studies. J Breast Cancer. 2017;20(4):327\u201332. https:\/\/doi.org\/10.4048\/jbc.2017.20.4.327.","journal-title":"J Breast Cancer"},{"issue":"2","key":"1876_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-014-3025-4","volume":"146","author":"JH Kim","year":"2014","unstructured":"Kim JH, Choi DH, Park W, Ahn SD, Kim SS, Ha SW, Kim K, Kim YB, Yea JW, Kang MK, Shin KH, Kim DW, Lee JH, Suh CO. Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11\u201304). Breast Cancer Res Treat. 2014;146(2):341\u20135. https:\/\/doi.org\/10.1007\/s10549-014-3025-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1876_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.radonc.2018.12.030","volume":"133","author":"MC Leonardi","year":"2019","unstructured":"Leonardi MC, Corrao G, Frassoni S, Vingiani A, Dicuonzo S, Lazzeroni M, Fodor C, Morra A, Gerardi MA, Rojas DP, Dell\u2019Acqua V, Marvaso G, Bassi FD, Galimberti VE, Veronesi P, Miglietta E, Cattani F, Zurrida S, Bagnardi V, Viale G, Orecchia R, Jereczek-Fossa BA. Ductal carcinoma in situ and intraoperative partial breast irradiation: who are the best candidates? Long-term outcome of a single institution series. Radiother Oncol. 2019;133:68\u201376. https:\/\/doi.org\/10.1016\/j.radonc.2018.12.030.","journal-title":"Radiother Oncol"},{"key":"1876_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.breast.2016.07.023","volume":"29","author":"A Toss","year":"2016","unstructured":"Toss A, Palazzo J, Berger A, Guiles F, Sendecki JA, Simone N, Anne R, Avery T, Jaslow R, Lazar M, Tsangaris T, Cristofanilli M. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: who to treat more and who to treat less. Breast. 2016;29:223\u201330. https:\/\/doi.org\/10.1016\/j.breast.2016.07.023.","journal-title":"Breast"},{"key":"1876_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.breast.2015.10.007","volume":"25","author":"N Poulakaki","year":"2016","unstructured":"Poulakaki N, Makris GM, Battista MJ, B\u00f6hm D, Petraki K, Bafaloukos D, Sergentanis TN, Siristatidis C, Chrelias C, Papantoniou N. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast? Breast. 2016;25:57\u201361. https:\/\/doi.org\/10.1016\/j.breast.2015.10.007.","journal-title":"Breast"},{"issue":"2","key":"1876_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4048\/jbc.2016.19.2.185","volume":"19","author":"JY Kim","year":"2016","unstructured":"Kim JY, Park K, Kang G, Kim HJ, Gwak G, Shin YJ. Predictors of recurrent ductal carcinoma in situ after breast-conserving surgery. J Breast Cancer. 2016;19(2):185\u201390. https:\/\/doi.org\/10.4048\/jbc.2016.19.2.185.","journal-title":"J Breast Cancer"},{"key":"1876_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.breast.2018.08.094","volume":"42","author":"O Ozkaya Akagunduz","year":"2018","unstructured":"Ozkaya Akagunduz O, Ergen A, Erpolat P, et al. Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. Breast. 2018;42:10\u20134. https:\/\/doi.org\/10.1016\/j.breast.2018.08.094.","journal-title":"Breast"},{"issue":"6797","key":"1876_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L\u00f8nning PE, B\u00f8rresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352. https:\/\/doi.org\/10.1038\/35021093.","journal-title":"Nature"},{"issue":"9","key":"1876_CR35","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24(9):2206\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdt303.","journal-title":"Ann Oncol"},{"issue":"1","key":"1876_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","volume":"27","author":"JYS Tsang","year":"2020","unstructured":"Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27(1):27\u201335. https:\/\/doi.org\/10.1097\/PAP.0000000000000232.","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"1876_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-020-05954-2","volume":"185","author":"M Sadeghalvad","year":"2021","unstructured":"Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. Immune microenvironment in different molecular subtypes of ductal breast carcinoma. Breast Cancer Res Treat. 2021;185(2):261\u201379. https:\/\/doi.org\/10.1007\/s10549-020-05954-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1876_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2022.03.019","volume":"64","author":"L Yang","year":"2022","unstructured":"Yang L, Shen M, Qiu Y, Tang T, Bu H. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. Breast. 2022;64:1\u20136. https:\/\/doi.org\/10.1016\/j.breast.2022.03.019.","journal-title":"Breast"},{"key":"1876_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4651","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhao X, Wang X, Jin K, Luo J, Yang Z, Mei X, Ma J, Shao Z, Zhang Z, Chen X, Guo X, Yu X. Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery. Cancer Med. 2022. https:\/\/doi.org\/10.1002\/cam4.4651.","journal-title":"Cancer Med"},{"issue":"5","key":"1876_CR40","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1245\/s10434-019-08184-z","volume":"27","author":"ZY Wu","year":"2020","unstructured":"Wu ZY, Kim HJ, Lee J, et al. Recurrence outcomes after Nipple-Sparing mastectomy and immediate breast reconstruction in patients with pure ductal carcinoma in situ. Ann Surg Oncol. 2020;27(5):1627\u201335. https:\/\/doi.org\/10.1245\/s10434-019-08184-z.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1876_CR41","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/modpathol.2015.79","volume":"28","author":"A Knopfelmacher","year":"2015","unstructured":"Knopfelmacher A, Fox J, Lo Y, Shapiro N, Fineberg S. Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. Mod Pathol. 2015;28(9):1167\u201373. https:\/\/doi.org\/10.1038\/modpathol.2015.79.","journal-title":"Mod Pathol"},{"key":"1876_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.breast.2017.06.010","volume":"35","author":"M Gennaro","year":"2017","unstructured":"Gennaro M, De Santis MC, Mariani L, Lo Vullo S, Cappelletti V, Agresti R, Cortinovis U, Paolini B, Di Cosimo S, Carcangiu ML, Daidone MG, Lozza L. Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. Breast. 2017;35:63\u20138. https:\/\/doi.org\/10.1016\/j.breast.2017.06.010.","journal-title":"Breast"},{"issue":"2","key":"1876_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-013-2755-z","volume":"142","author":"KP Siziopikou","year":"2013","unstructured":"Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013;142(2):415\u201321. https:\/\/doi.org\/10.1007\/s10549-013-2755-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1876_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cncr.25399","volume":"117","author":"HM Kuerer","year":"2011","unstructured":"Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011;117(1):39\u201347. https:\/\/doi.org\/10.1002\/cncr.25399.","journal-title":"Cancer"},{"issue":"11","key":"1876_CR45","first-page":"1113","volume":"2","author":"K Liang","year":"2003","unstructured":"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2(11):1113\u201320.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"1876_CR46","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1200\/JCO.20.02824","volume":"39","author":"MA Cobleigh","year":"2021","unstructured":"Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase III clinical trial. J Clin Oncol. 2021;39(21):2367\u201374. https:\/\/doi.org\/10.1200\/JCO.20.02824.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1876_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5603\/RPOR.a2021.0026","volume":"26","author":"GD Lewis","year":"2021","unstructured":"Lewis GD, Haque W, Farach A, Hatch SS, Butler EB, Niravath PA, Schwartz MR, Bonefas E, Teh BS. The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast. Rep Pract Oncol Radiother. 2021;26(2):179\u201387. https:\/\/doi.org\/10.5603\/RPOR.a2021.0026.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"1","key":"1876_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","volume":"54","author":"S Ahn","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34\u201344. https:\/\/doi.org\/10.4132\/jptm.2019.11.03.","journal-title":"J Pathol Transl Med"},{"issue":"1","key":"1876_CR49","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118\u201345. https:\/\/doi.org\/10.1200\/JCO.2006.09.2775.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1876_CR50","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1876_CR51","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364\u201382. https:\/\/doi.org\/10.5858\/arpa.2018-0902-SA.","journal-title":"Arch Pathol Lab Med"},{"key":"1876_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123\u201335. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.016.","journal-title":"Semin Cancer Biol"},{"key":"1876_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/jca.2.232","volume":"2","author":"SA Lari","year":"2011","unstructured":"Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2:232\u201361. https:\/\/doi.org\/10.7150\/jca.2.232.","journal-title":"J Cancer"},{"key":"1876_CR54","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2017.00248","volume":"7","author":"KL Gorringe","year":"2017","unstructured":"Gorringe KL, Fox SB. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248. https:\/\/doi.org\/10.3389\/fonc.2017.00248.","journal-title":"Front Oncol"},{"issue":"5","key":"1876_CR55","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1055-9965.EPI-18-0976","volume":"28","author":"LL Visser","year":"2019","unstructured":"Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019;28(5):835\u201345. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0976.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"1876_CR56","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/bjc.2012.41","volume":"106","author":"E Rakovitch","year":"2012","unstructured":"Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L. HER2\/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106(6):1160\u20135. https:\/\/doi.org\/10.1038\/bjc.2012.41.","journal-title":"Br J Cancer"},{"issue":"9","key":"1876_CR57","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jnci\/djq101","volume":"102","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627\u201337. https:\/\/doi.org\/10.1093\/jnci\/djq101.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1876_CR58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A. Role of p53 in Cell DEATH AND HUMAN CANCERS. Cancers (Basel). 2011;3(1):994\u20131013. https:\/\/doi.org\/10.3390\/cancers3010994.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1876_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jss.2006.10.045","volume":"140","author":"MA de Roos","year":"2007","unstructured":"de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res. 2007;140(1):109\u201314. https:\/\/doi.org\/10.1016\/j.jss.2006.10.045.","journal-title":"J Surg Res"},{"issue":"3","key":"1876_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00428-018-2416-z","volume":"473","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Thike AA, Koh VCY, Sasano H, Tan PH. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Arch. 2018;473(3):275\u201383. https:\/\/doi.org\/10.1007\/s00428-018-2416-z.","journal-title":"Virchows Arch"},{"issue":"18","key":"1876_CR61","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-15-0506","volume":"75","author":"MC Abba","year":"2015","unstructured":"Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, Butti M, Takata Y, Gaddis S, Shen J, Estecio MR, Sahin AA, Aldaz CM. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 2015;75(18):3980\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0506.","journal-title":"Cancer Res"},{"issue":"7","key":"1876_CR62","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-07-1465","volume":"14","author":"A Vincent-Salomon","year":"2008","unstructured":"Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O. Breast cancer study group of the Institut Curie. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14(7):1956\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1465.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1876_CR63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/path.3990","volume":"227","author":"L Hernandez","year":"2012","unstructured":"Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A\u2019Hern R, Marchi\u00f2 C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012;227(1):42\u201352. https:\/\/doi.org\/10.1002\/path.3990.","journal-title":"J Pathol"},{"issue":"7","key":"1876_CR64","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/modpathol.2017.21","volume":"30","author":"JB Pang","year":"2017","unstructured":"Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O\u2019Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod Pathol. 2017;30(7):952\u201363. https:\/\/doi.org\/10.1038\/modpathol.2017.21.","journal-title":"Mod Pathol"},{"issue":"2","key":"1876_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-019-05401-x","volume":"178","author":"CY Lin","year":"2019","unstructured":"Lin CY, Vennam S, Purington N, Lin E, Varma S, Han S, Desa M, Seto T, Wang NJ, Stehr H, Troxell ML, Kurian AW, West RB. Genomic landscape of ductal carcinoma in situ and association with progression. Breast Cancer Res Treat. 2019;178(2):307\u201316. https:\/\/doi.org\/10.1007\/s10549-019-05401-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1876_CR66","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1530\/ERC-19-0019","volume":"26","author":"MC Agahozo","year":"2019","unstructured":"Agahozo MC, Sieuwerts AM, Doebar SC, Verhoef EI, Beaufort CM, Ruigrok-Ritstier K, de Weerd V, Sleddens HFBM, Dinjens WNM, Martens JWM, van Deurzen CHM. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Endocr Relat Cancer. 2019;26(5):471\u201382. https:\/\/doi.org\/10.1530\/ERC-19-0019.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1876_CR67","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s42003-021-01959-9","volume":"4","author":"S Nagasawa","year":"2021","unstructured":"Nagasawa S, Kuze Y, Maeda I, Kojima Y, Motoyoshi A, Onishi T, Iwatani T, Yokoe T, Koike J, Chosokabe M, Kubota M, Seino H, Suzuki A, Seki M, Tsuchihara K, Inoue E, Tsugawa K, Ohta T, Suzuki Y. Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. Commun Biol. 2021;4(1):438. https:\/\/doi.org\/10.1038\/s42003-021-01959-9.","journal-title":"Commun Biol"},{"issue":"9","key":"1876_CR68","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1158\/1078-0432.CCR-13-2267","volume":"20","author":"RA Sakr","year":"2014","unstructured":"Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS, King TA. PI3K pathway activation in high-grade ductal carcinoma in situ\u2013implications for progression to invasive breast carcinoma. Clin Cancer Res. 2014;20(9):2326\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2267.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1876_CR69","doi-asserted-by":"publisher","first-page":"e116054","DOI":"10.1371\/journal.pone.0116054","volume":"9","author":"A Sueta","year":"2014","unstructured":"Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS ONE. 2014;9(12):e116054. https:\/\/doi.org\/10.1371\/journal.pone.0116054.","journal-title":"PLoS ONE"},{"key":"1876_CR70","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.221","author":"JW Kim","year":"2022","unstructured":"Kim JW, Lim AR, You JY, Lee JH, Song SE, Lee NK, Jung SP, Cho KR, Kim CY, Park KH. PIK3CA mutation is associated with poor response to HER2-targeted therapy in breast cancer patients. Cancer Res Treat. 2022. https:\/\/doi.org\/10.4143\/crt.2022.221.","journal-title":"Cancer Res Treat"},{"issue":"7","key":"1876_CR71","first-page":"3067","volume":"12","author":"WP Chung","year":"2022","unstructured":"Chung WP, Huang WL, Lee CH, Hsu HP, Huang WL, Liu YY, Su WC. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations. Am J Cancer Res. 2022;12(7):3067\u201382.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"1876_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3727\/105221615X14399878166113","volume":"16","author":"M Takaku","year":"2015","unstructured":"Takaku M, Grimm SA, Wade PA. GATA3 in breast cancer: tumor suppressor or oncogene? Gene Expr. 2015;16(4):163\u20138. https:\/\/doi.org\/10.3727\/105221615X14399878166113.","journal-title":"Gene Expr"},{"issue":"31","key":"1876_CR73","doi-asserted-by":"publisher","first-page":"50570","DOI":"10.18632\/oncotarget.10843","volume":"8","author":"M Jeon","year":"2016","unstructured":"Jeon M, You D, Bae SY, Kim SW, Nam SJ, Kim HH, Kim S, Lee JE. Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget. 2016;8(31):50570\u201381. https:\/\/doi.org\/10.18632\/oncotarget.10843.","journal-title":"Oncotarget"},{"issue":"6","key":"1876_CR74","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.3892\/ol.2017.7051","volume":"14","author":"P Guo","year":"2017","unstructured":"Guo P, Pu T, Chen S, Qiu Y, Zhong X, Zheng H, Chen L, Bu H, Ye F. Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome. Oncol Lett. 2017;14(6):6562\u201370. https:\/\/doi.org\/10.3892\/ol.2017.7051.","journal-title":"Oncol Lett"},{"issue":"6","key":"1876_CR75","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/2159-8290.CD-11-0261","volume":"1","author":"F Ciardiello","year":"2011","unstructured":"Ciardiello F, Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov. 2011;1(6):472\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0261.","journal-title":"Cancer Discov"},{"issue":"2","key":"1876_CR76","first-page":"127","volume":"37","author":"S Steinman","year":"2007","unstructured":"Steinman S, Wang J, Bourne P, Yang Q, Tang P. Expression of cytokeratin markers, ER-alpha, PR, HER-2\/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37(2):127\u201334.","journal-title":"Ann Clin Lab Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01876-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T03:31:33Z","timestamp":1673839893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01876-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}